𝔖 Bobbio Scriptorium
✦   LIBER   ✦

The use of entacapone in patients with advanced Parkinson’s disease: 2 years’ experience

✍ Scribed by C. Paci; S. Sanguigni; T. Carboni; R. Gobbato; L. Curatola

Publisher
Springer Milan
Year
2003
Tongue
English
Weight
30 KB
Volume
24
Category
Article
ISSN
1590-1874

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Entacapone improves absorption of a coad
Entacapone improves absorption of a coadministered salt in patients with Parkinson's disease
✍ Thomas Müller; Dirk Woitalla; Oliver Goetze; Christoph Erdmann 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 418 KB

## Abstract Entacapone (EN) improves the efficacy of levodopa/dopadecarboxylase inhibitor (LD/DDI) formulations by inhibition of the enzyme catechol‐__O__‐methyltransferase (COMT). COMT inhibition also promotes the synthesis of basic LD metabolites, whereas DDI support the composition of acidic LD

Use of complementary therapies in patien
Use of complementary therapies in patients with Parkinson's disease in Singapore
✍ Louis C.S. Tan; Puay-Ngoh Lau; Roland Dominic G. Jamora; Edwin S.Y. Chan 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 87 KB 👁 1 views

## Abstract To determine the frequency and spectrum of complementary therapy (CT) use and its association with sociodemographic or disease‐specific characteristics among Asian patients with Parkinson's disease (PD) in Singapore, we interviewed 159 patients using a structured questionnaire. Sixty‐on

Therapeutic experience with the new dopa
Therapeutic experience with the new dopamine agonist CU 32-085 in advanced Parkinson's disease
✍ H. Biesemeyer; H. P. Ludin; E. Ringwald 📂 Article 📅 1983 🏛 Springer 🌐 English ⚖ 279 KB

Twenty patients with advanced progressing Parkinson's disease have been treated with the 8-alpha-ergoline CU 32-085 in combination therapy for 3 months. With a mean daily dose of 12.65 mg, CU 32-085 together with levodopa plus a decarboxylase inhibitor produced a significant reduction in akinesia, r